Home > Insider Trading > Filing (0001739614-24-000037)

Filing Details

Accession Number:: 0001739614-24-000037
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-09-03 17:31:03
Reporting Period:: 2024-08-29

Accepted Time:: 2024-09-03 17:31:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
2007919	Inhibrx Biosciences Inc.	INBX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1366074	Mark Lappe	C/O Inhibrx Biosciences, Inc. 11025 North Torrey Pines Road, Suite 140 La Jolla CA 92037	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-08-29	10,000	$14.03	135,000	No	4	P	Indirect	By Lappe Descendants' Trust
Common Stock	Acquisiton	2024-08-30	10,000	$14.02	145,000	No	4	P	Indirect	By Lappe Descendants' Trust
Common Stock	Acquisiton	2024-09-03	15,288	$15.66	160,288	No	4	P	Indirect	By Lappe Descendants' Trust
Common Stock	Acquisiton	2024-09-03	4,712	$16.31	165,000	No	4	P	Indirect	By Lappe Descendants' Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Lappe Descendants' Trust
No	4	P	Indirect	By Lappe Descendants' Trust
No	4	P	Indirect	By Lappe Descendants' Trust
No	4	P	Indirect	By Lappe Descendants' Trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	621,548	Indirect	By the Lappe Family Trust
Common Stock	54,865	Indirect	The Mark Paul Lappe Roth IRA

Footnotes

The shares were purchased in multiple transactions at prices ranging from $13.9079 to $14.245, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.
The shares were purchased in multiple transactions at prices ranging from $13.96 to $14.13, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
The shares were purchased in multiple transactions at prices ranging from $15.115 to $16.11, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
The shares were purchased in multiple transactions at prices ranging from $16.115 to $16.465, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.